*To the Editor*:

We read with great interest the article titled "MicroRNA-145 Antagonism Reverses TGF-β Inhibition of F508del CFTR Correction in Airway Epithelia" by Lutful Kabir and colleagues ([@bib1]). In this paper, the authors demonstrate that miR-145 mediates TGF-β (transforming growth factor-β) inhibition of synthesis and function of CFTR (cystic fibrosis transmembrane conductance regulator) in cystic fibrosis (CF) airway epithelia. Interestingly, they found that antagonists of miR-145 were able to interrupt TGF-β signaling and restore F508del CFTR modulation. Therefore, they suggested that miR-145 targeting may provide a novel therapeutic opportunity to enhance the benefit of F508del CFTR correction in CF epithelia. In agreement with this, we have elsewhere published data supporting the use of miR-145 targeting in CF, based on an antisense peptide nucleic acid (PNA) to target miR-145-5p (PNA-a145) and enhance expression of the *CFTR* gene, which we analyzed at mRNA (qRT-PCR) and protein (Western blotting) levels ([@bib2]). In support of the conclusion by Lutful Kabir and colleagues, our data suggest the use of suitably delivered antisense molecules targeting miR-145-5p to enhance the expression of CFTR ([@bib2]).

With respect to a possible microRNA (miRNA)-based therapeutic option, one limitation is of course the presence of more than 300 *CFTR* gene disease-causing mutations ([www.genet.sickkids.on.ca/cftr/](http://www.genet.sickkids.on.ca/cftr/)) ([@bib3]). Besides the *CFTR* mutation leading to the deletion of the phenylalanine in position 508 (F508del CFTR), accounting for 50--90% CF chromosomes, most CF-causing mutations are missense (42%), nonsense (10%), frameshift (15%), splicing (13%), in-frame deletion/insertion (2%), and promoter (0.5%) mutations, which are now operationally categorized in six classes of molecular defects of the CFTR protein ([@bib3]).

In consideration of these different molecular defects, it is expected that targeting miR-145 could be useful for type IV (less function), V (less protein), and VI (less stable protein) CFTR defects. For CFTR defects such as type I (no protein), II (no traffic), and III (no function), miR-145 targeting may be considered only in combination with other therapeutic protocols. In conclusion, in agreement with Lutful Kabir and colleagues, and considering the increasing relevance of RNA-targeted therapies ([@bib4]), combined therapy with innovative oligonucleotides or peptide--nucleotide chimeras targeting miR-145 might be considered together with CFTR correctors such as lumacaftor, tezacaftor ([@bib1], [@bib3]), and 4,6,4′-trimethylangelicin ([@bib3], [@bib5]).

In addition, using next-generation sequencing of the miRNome, we recently observed that the majority of miRNAs (81.6%) are not modulated in Calu-3 cells treated with the anti-miR145 PNA (unpublished results). On the other hand, we observed that inhibition of miR-145-5p with PNA might also be accompanied by coinhibition of other miRNAs (12.5%), among which of great interest in our opinion is miR-155-3p. Our next-generation sequencing data, validated by qRT-PCR and droplet digital RT-PCR, demonstrated that treatment of Calu-3 cells with PNA-a145 resulted in inhibition of miR-145-5p and miR-155-3p by 34--43% and 42--44%, respectively. This is of interest because miR-155-3p upregulation has been reported to be responsible for hyperactivating IL-8, thereby amplifying the deleterious effects of excessive inflammation on CF lung tissues ([@bib6]). Therefore, in addition to upregulation of CFTR ([@bib1], [@bib2]), PNA-mediated targeting of miR-145-5p might be expected to lead to downregulation of IL-8, possibly combining two activities of great interest in CF therapy, i.e., the rescue and potentiation of mutant CFTR protein and the control of lung inflammation.
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